

**Lantheus Holdings, Inc.**  
**Supplemental Revenue Information**  
(unaudited)

Beginning with the first quarter of 2021, the Company changed its product revenues presentation, where product revenues are now presented net of rebates and allowances. Rebates and allowances for DEFINITY and TechneLite comprised approximately 98% of the Company's total rebates and allowances for the years ended 2020 and 2019.

The below table presents quarterly revenues for DEFINITY and TechneLite for the respective years:

**Gross Revenue - Excluding Rebates and Allowances**

<b>(in millions)</b>	<b>2019</b>					<b>2020</b>				
	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>Total</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>Total</b>
DEFINITY	\$ 51.1	\$ 54.6	\$ 52.4	\$ 59.4	\$ 217.5	\$ 56.8	\$ 40.4	\$ 55.4	\$ 60.7	\$ 213.3
TechneLite	24.1	20.1	21.7	20.6	86.5	23.1	18.9	21.5	22.7	86.2
<b>Growth Rate %</b>										
DEFINITY	14.5 %	18.5 %	19.7 %	22.3 %	18.8 %	11.1 %	(26.1)%	5.8 %	2.3 %	(1.9)%
TechneLite	12.9 %	(14.4)%	(29.0)%	(11.9)%	(12.4)%	(4.3)%	(6.0)%	(1.2)%	10.4 %	(0.4)%

**Net Revenue - Including Rebates and Allowances**

<b>(in millions)</b>	<b>2019</b>					<b>2020</b>				
	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>Total</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>Total</b>
DEFINITY	\$ 47.6	\$ 50.7	\$ 48.8	\$ 55.3	\$ 202.4	\$ 52.5	\$ 37.1	\$ 50.4	\$ 55.9	\$ 195.9
TechneLite	23.9	19.8	21.5	20.3	85.5	22.8	18.7	21.1	22.4	85.0
<b>Growth Rate %</b>										
DEFINITY	13.3 %	17.9 %	19.1 %	21.8 %	18.1 %	10.4 %	(26.8)%	3.2 %	1.2 %	(3.2)%
TechneLite	12.7 %	(14.8)%	(29.4)%	(12.3)%	(12.8)%	(4.6)%	(5.8)%	(1.7)%	10.3 %	(0.6)%

**Lantheus Holdings, Inc.**  
**Supplemental Net Revenue Information**  
(unaudited)

Beginning with the first quarter of 2021, the Company changed its product revenues presentation.

The below table presents quarterly revenues for the respective years:

<b>(in millions)</b>	<b>Net Revenue - Including Rebates and Allowances</b>									
	<b>2019</b>					<b>2020</b>				
	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>Total</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>Total</b>
DEFINITY	\$ 47.6	\$ 50.7	\$ 48.8	\$ 55.3	\$ 202.4	\$ 52.5	\$ 37.1	\$ 50.4	\$ 55.9	\$ 195.9
TechneLite	23.9	19.8	21.5	20.3	85.5	22.8	18.7	21.1	22.4	85.0
Other precision diagnostics	12.5	12.4	12.8	11.4	49.1	13.0	7.1	8.6	8.0	36.7
Total precision diagnostics	84.0	82.9	83.1	87.0	337.0	88.3	62.9	80.1	86.3	317.6
Radiopharmaceutical oncology	2.1	2.4	2.3	1.9	8.7	2.0	2.2	3.3	2.6	10.1
Strategic partnerships and other	0.4	0.4	0.4	0.4	1.6	0.4	0.9	5.1	5.3	11.7
<b>Total revenues</b>	<b>\$ 86.5</b>	<b>\$ 85.7</b>	<b>\$ 85.8</b>	<b>\$ 89.3</b>	<b>\$ 347.3</b>	<b>\$ 90.7</b>	<b>\$ 66.0</b>	<b>\$ 88.5</b>	<b>\$ 94.2</b>	<b>\$ 339.4</b>